210 related articles for article (PubMed ID: 38580332)
21. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
22. CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
Drerup JM; Deng Y; Pandeswara SL; Padrón ÁS; Reyes RM; Zhang X; Mendez J; Liu A; Clark CA; Chen W; Conejo-Garcia JR; Hurez V; Gupta H; Curiel TJ
Cancer Res; 2020 Nov; 80(22):5063-5075. PubMed ID: 32948605
[TBL] [Abstract][Full Text] [Related]
23. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
24. Aspergillus fumigatus Cell Wall α-(1,3)-Glucan Stimulates Regulatory T-Cell Polarization by Inducing PD-L1 Expression on Human Dendritic Cells.
Stephen-Victor E; Karnam A; Fontaine T; Beauvais A; Das M; Hegde P; Prakhar P; Holla S; Balaji KN; Kaveri SV; Latgé JP; Aimanianda V; Bayry J
J Infect Dis; 2017 Dec; 216(10):1281-1294. PubMed ID: 28968869
[TBL] [Abstract][Full Text] [Related]
25. Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer.
Chen Z; Hu K; Feng L; Su R; Lai N; Yang Z; Kang S
Cancer Sci; 2018 Jun; 109(6):1753-1763. PubMed ID: 29675979
[TBL] [Abstract][Full Text] [Related]
26. Programmed death ligand 1 (PD-L1) plays a vital part in DC tolerogenicity induced by IFN-γ.
Švajger U; Tešić N; Rožman P
Int Immunopharmacol; 2021 Oct; 99():107978. PubMed ID: 34298399
[TBL] [Abstract][Full Text] [Related]
27. CD27 expression on Treg cells limits immune responses against tumors.
Muth S; Klaric A; Radsak M; Schild H; Probst HC
J Mol Med (Berl); 2022 Mar; 100(3):439-449. PubMed ID: 34423375
[TBL] [Abstract][Full Text] [Related]
28. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
29. The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?
Galati D; Zanotta S; Bocchino M; De Filippi R; Pinto A
Cancer Immunol Immunother; 2021 Jul; 70(7):1797-1809. PubMed ID: 33386466
[TBL] [Abstract][Full Text] [Related]
30. Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1.
Sirvent S; Soria I; Cirauqui C; Cases B; Manzano AI; Diez-Rivero CM; Reche PA; López-Relaño J; Martínez-Naves E; Cañada FJ; Jiménez-Barbero J; Subiza J; Casanovas M; Fernández-Caldas E; Subiza JL; Palomares O
J Allergy Clin Immunol; 2016 Aug; 138(2):558-567.e11. PubMed ID: 27177779
[TBL] [Abstract][Full Text] [Related]
31. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors.
Iwata-Kajihara T; Sumimoto H; Kawamura N; Ueda R; Takahashi T; Mizuguchi H; Miyagishi M; Takeda K; Kawakami Y
J Immunol; 2011 Jul; 187(1):27-36. PubMed ID: 21632716
[TBL] [Abstract][Full Text] [Related]
32. Tolerogenic signaling by pulmonary CD1c+ dendritic cells induces regulatory T cells in patients with chronic obstructive pulmonary disease by IL-27/IL-10/inducible costimulator ligand.
Tsoumakidou M; Tousa S; Semitekolou M; Panagiotou P; Panagiotou A; Morianos I; Litsiou E; Trochoutsou AI; Konstantinou M; Potaris K; Footitt J; Mallia P; Zakynthinos S; Johnston SL; Xanthou G
J Allergy Clin Immunol; 2014 Oct; 134(4):944-954.e8. PubMed ID: 25051954
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy.
Teramoto K; Ohshio Y; Fujita T; Hanaoka J; Kontani K
J Cancer Res Clin Oncol; 2013 May; 139(5):861-70. PubMed ID: 23411688
[TBL] [Abstract][Full Text] [Related]
34. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
35. IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer.
Gao W; Wen H; Liang L; Dong X; Du R; Zhou W; Zhang X; Zhang C; Xiang R; Li N
Theranostics; 2021; 11(6):2564-2580. PubMed ID: 33456560
[No Abstract] [Full Text] [Related]
36. Crosstalk of regulatory T cells and tolerogenic dendritic cells prevents contact allergy in subjects with low zone tolerance.
Luckey U; Schmidt T; Pfender N; Romer M; Lorenz N; Martin SF; Bopp T; Schmitt E; Nikolaev A; Yogev N; Waisman A; Jakob T; Steinbrink K
J Allergy Clin Immunol; 2012 Sep; 130(3):781-797.e11. PubMed ID: 22935591
[TBL] [Abstract][Full Text] [Related]
37. Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells.
Carenza C; Calcaterra F; Oriolo F; Di Vito C; Ubezio M; Della Porta MG; Mavilio D; Della Bella S
Front Immunol; 2019; 10():1325. PubMed ID: 31244860
[TBL] [Abstract][Full Text] [Related]
38. Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1.
Amarnath S; Costanzo CM; Mariotti J; Ullman JL; Telford WG; Kapoor V; Riley JL; Levine BL; June CH; Fong T; Warner NL; Fowler DH
PLoS Biol; 2010 Feb; 8(2):e1000302. PubMed ID: 20126379
[TBL] [Abstract][Full Text] [Related]
39. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
[TBL] [Abstract][Full Text] [Related]
40. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
Front Immunol; 2019; 10():1939. PubMed ID: 31475002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
